In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to discuss recent artificial intelligence (AI) initiatives in the news. She then welcomes Jane Hermansen, manager of Mayo Clinic Laboratories’ Outreach Program, to discuss the value of outreach programs in strengthening laboratories and supporting broader healthcare systems.

• AI’s potential and limitations (00:01): Learn what’s next and the challenges that remain as Drs. Pritt and Morice discuss recent stories about AI in healthcare.
• Value of outreach (07:30): Discover how laboratory outreach programs support their organizations, delivering benefits that range from improved patient care to lower testing costs and growth across health system service lines.
• Getting the most from outreach (15:54): Learn the three most important things lab leaders can do to get the greatest value from their outreach program.
• The future of outreach (17:53): Get insights on how outreach may evolve in the coming years as healthcare changes.

Resources

• Fortune: A decade after the ‘Godfather of AI’ said radiologists are obsolete, salaries are $571K and growing
• “Answers From the Lab” podcast: Digital Advances: What's Next for Clinical Diagnostics?
• Personalized pathways through digital diagnostics: A Q&A with Chris Garcia, M.D.
• Outreach & Business Solutions
• Own your lab: Hospital-owned labs generate long-term financial and clinical value
• Leveraging the Laboratory Conference

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to discuss recent industry news and how clinical diagnostics are powering more personalized care. Together, they explore:

• Point-of-care testing in outbreak response (00:29): Hear about the potential and limitations of point-of-care testing during disease outbreaks.
• A rare type of Lyme disease (02:46): Learn about the spread of the second known pathogen to cause Lyme disease in the U.S.
• The evolution of AI (04:50): Dr. Morice shares insights from a recent conference, highlighting the shift from discussing artificial intelligence’s potential to scaling real-world clinical applications.
• Personalized medicine and diagnostics (06:07): Discover how clinical diagnostics are driving personalized medicine and how data will shape its future.

Resources

• Four ways diagnostics are driving more personalized care
• "Answers From the Lab" podcast: Advancing Precision Medicine Through Therapeutic Tests
• "Answers From the Lab" podcast: Risks Increase as Ticks, Mosquitoes, and Similar Vectors Spread
• Therapeutics testing: Discover the differences

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to discuss updates on the Protecting Access to Medicare Act (PAMA) and other policy changes affecting clinical diagnostics. Later, Dr. Pritt welcomes Ann Moyer, M.D., Ph.D., a molecular genetic pathologist at Mayo Clinic and chair of the hereditary genetics practice, to explore how precision therapeutics are improving cancer treatments.

• PAMA update (00:01): Get the latest on PAMA as the first data collection period begins, including ongoing efforts to advance the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act.
• Policy changes influencing diagnostics (04:09): Learn how evolving reimbursement policies for blood-based cancer screening and a proposed CLIA modernization bill may impact the field.
• Pharmacogenomic tests improving cancer care (08:14): Discover how pharmacogenomics are benefiting patients with cancer, the benefits of medication-based testing, and how this field is advancing.

Resources

• CMS: CLFS & PAMA reporting and resources
• Precision Oncology Therapeutics: Personalized cancer treatment
• Answers From the Lab: Genetic Tests Identify Risk of Irinotecan-Induced Toxicity: John Logan Black, M.D.
• Answers From the Lab: Genetic Tests Identify Risk of Fluoropyrimidine-Induced Toxicity: Ann Moyer, M.D., Ph.D.